TAG applauds Indian TB activists in opposing patents for critical TB prevention drugs

Civil society takes legal action to contest patent applications filed by Sanofi on fixed-dose combinations of two decades-old drugs used to prevent TB.

Read More →

Interactive TB mapping tool

The Stop TB Partnership interactive mapping TB tool is now LIVE.

Read More →

ATS, CDC, ERS and IDSA publish new clinical guideline for the treatment and prevention of drug-resistant TB

New guideline emphasizes treatment of drug-resistant TB with all-oral regimens and provides recommendations for treatment of all contacts to multidrug-resistant TB patients.

Read More →

Are pretomanid-containing regimens for TB a victory or a victory narrative?

"Given the evidence base available to us currently, can we claim pretomanid a victory? We think more research is needed before pretomanid can be celebrated as a promising treatment for people with tuberculosis."

Read More →

Time to lower the price of Xpert cartridges to US$ 5

Advocates request Cepheid immediately reduce the price of Xpert tests to US$ 5, inclusive of service and maintenance; the company responds they are “not able to predict the amount of further reductions or when they may be available.”

Read More →

Survivors Statement

Presented in the Opening Ceremony of the 50th Union World Conference on Lung Health by survivor Nandita Venkatesan.

Read More →

WHO updates policy for the use of TB LAM test

The World Health Organization now recommends more broader use of urinary LAM assays for diagnosis of TB in people living with HIV.

Read More →

TAG’s 2019 Pipeline Report: Three TB sections released

The sections provide an overview of TB diagnostics, vaccines and treatment.

Read More →

Public investments in TB medicine bedaquiline far exceed those of developer Johnson & Johnson

Quantification of investments in the development of bedaquiline finds total public and philanthropic expenditures are three to five times those of Johnson & Johnson.

Read More →

Protestors demand Cepheid halve the price of GeneXpert TB tests to US$5

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.

Read More →

Page 1 of 102 · Total posts: 10

1 2 Last→